phosphatidylcholine

Phosphatidylcholines,soya (Soybean phosphatidylcholine) is a phosphatidylcholine from soybean used in the preparation of liposomes.

Palmitoyldocosahexaenoyl phosphatidylcholine is a polyunsaturated fatty acid that mimics special cell membrane structural domain lipids.

Lysophosphatidylcholine 18:2 is a mouse metabolite functionally related to linoleic acid.18:2 LysoPC is a major component of oxidized low-density lipoproteins (LDLs), and low plasma levels of LPC 18:2 have been associated with metabolic disorders such as impaired glucose tolerance, insulin resistance, type 2 diabetes, and coronary artery disease.1-Linoleoyl 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC is also a substrate for the generation of lysophosphatidic acid (LPA) from Autotaxin (LysoPLD), which plays an important role in cell motility.

Citicoline (CDP-Choline) is an intermediate in the synthesis of phosphatidylcholine, a component of cell membranes. Citicoline exerts neuroprotective effects.

Citicoline sodium (CDP-choline) is an endogenous intermediate in the synthesis of phosphatidylcholine. It also serves as a choline donor in the biosynthesis of the neurotransmitter acetylcholine. Citicoline sodium demonstrates protective effects in cerebral ischemia, traumatic brain injury, and memory disorders. Exogenous administration of citicoline to rodents (500 mg kg i.p. immediately after ischemia and at 3-h reperfusion) has been shown to stimulate the synthesis of phosphatidylcholine, sphingomyelin, and cardiolipin and to attenuate the release of arachidonic acid and the accumulation of ceramide.

Lecithin (L-alpha-phosphatidylcholine) is considered a safe source of conventional phospholipids. Phospholipids can change the fatty acid composition and microstructure of animal cell membrane.

Phosphatidylserine is a naturally occurring phospholipid that comprises 2-10% of total phospholipids in mammals and is enriched in the central nervous system, particularly the retina. It is anionic and found mainly on the inner leaflet of the cell membrane. It is biosynthesized from phosphatidylcholine or phosphatidylethanolamine by phosphatidyl synthase 1 (PSS1) or PSS2, respectively, in the endoplasmic reticulum and can be reversibly converted back by the same enzymes. It can also be irreversibly converted to phosphatidylethanolamine by phosphatidylserine decarboxylase in the mitochondria. Phosphatidylserine binds to T cell immunoglobulin mucin type 1 (TIM-1) and TIM-4 receptors as well as brain-specific angiogenesis inhibitor 1 (BAI1), leading to anti-inflammatory and anti-atherosclerotic effects. It is also a cofactor involved in the activation of various signaling pathways through activation of protein kinase C, neutral sphingomyelinase, and c-Raf-1 protein kinase among others. Phosphatidylserine is externalized during apoptosis by scramblases in the plasma membrane as a signal for phagocytes to engulf the cell. Phosphatidylserines (bovine) is a mixture of bovine phosphatidylserines containing fatty acids with variable chain lengths at the sn-1 and sn-2 positions.

Lyso-globotriaosylceramide is a form of globotriaosylceramide that is lacking the fatty acyl group. It binds to Shiga toxin 1 (Stx1) in the presence of cholesterol and phosphatidylcholine but does not bind Stx2. It also reduces viability and aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate when used at concentrations of 50 and 1 μM, respectively. Lyso-globotriaosylceramide accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. It also accumulates in the urine, kidney, and plasma of patients with Fabry disease. Lyso-globotriaosylceramide levels decrease in response to administration of the α-galactosidase inhibitor 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease. Decreases in plasma and urine concentrations of lyso-globotriaosylceramide have been used as a biomarker for efficacy of enzyme replacement therapy (ERT) and other therapies in the treatment of Fabry disease.

Glycerophosphocholine ((S)-Glycerolphosphocholine) is an intracellular metabolite involved in the metabolism of phosphatidylcholine and is utilized for studying the endogenous choline supply within cells. Additionally, Glycerophosphocholine serves as a supplement in research focused on brain-related disorders.